JAMES CHENG-CHUNG WEI2026-10-162026-10-162026-03-01Pure ID: 15309467Pure UUID: 205dbfa3-befa-41b6-aa24-0858efb686b310.1002/art.43332https://www.scopus.com/pages/publications/105023894865https://scholars.csmu.edu.tw/handle/123456789/33391Objective: The optimal treatment strategy for rheumatoid arthritis–associated interstitial lung disease (RA-ILD) remains uncertain, and direct comparative data between biologics are limited. This study aimed to evaluate the effectiveness and safety of abatacept compared with rituximab in patients with RA-ILD. Methods: An emulated target trial was designed using the TriNetX US Collaborative Network database, including patients with RA-ILD, diagnosed between 2007 and 2024. Propensity score matching was used to balance baseline characteristics between the two treatment groups (abatacept and rituximab). The primary outcome was all-cause mortality, and secondary outcomes included respiratory events, medical utilization, and infection-related adverse events. Hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated to use Cox proportional hazards models. Results: In total, 1,615 patients per group were identified after matching for analysis. Abatacept was associated with a significantly lower risk of all-cause mortality compared with rituximab (HR, 0.689; 95% CI, 0.581–0.818) and a reduced risk of mechanical ventilation (HR, 0.698; 95% CI, 0.521–0.934). The subgroup analyses yielded consistent findings. Sensitivity analyses excluding patients with concomitant connective tissue diseases also demonstrated consistent results (mortality: HR, 0.679; 95% CI, 0.570–0.810), reinforcing the robustness of the findings. Conclusion: Abatacept was associated with a lower risk of mortality compared with rituximab in patients with RA-ILD. Because clinicians may preferentially reserve abatacept for less aggressive RA-ILD, residual confounding by indication cannot be excluded; thus, the association should not be interpreted as proof of causality. Prospective randomized trials are needed to confirm whether abatacept confers a true survival advantage. (Figure presented.).11enjournal article